|本期目录/Table of Contents|

[1]吴健,王晶晶综述,杨鲸蓉,等.组蛋白去乙酰化酶抑制剂对食管癌细胞抗肿瘤活性及其相关机制的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2018,20(04):394-398.[doi:10.3969/j.issn.1672-271X.2018.04.015]
点击复制

组蛋白去乙酰化酶抑制剂对食管癌细胞抗肿瘤活性及其相关机制的研究进展()

《医学研究与战创伤救治》(原医学研究生学报)[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年04期
页码:
394-398
栏目:
综述
出版日期:
2018-07-20

文章信息/Info

Title:
-
作者:
吴健王晶晶综述杨鲸蓉曾志勇审校
作者单位:350025福州,福建医科大学福总临床学院(吴健、王晶晶);350025福州,福州总医院心胸外科(杨鲸蓉、曾志勇)
Author(s):
-
关键词:
组蛋白去乙酰化酶组蛋白去乙酰化酶抑制剂食管癌肿瘤
Keywords:
-
分类号:
R966
DOI:
10.3969/j.issn.1672-271X.2018.04.015
文献标志码:
A
摘要:
食管癌是威胁人类身体健康的严重疾病之一,传统抗肿瘤药物因选择性差易引起较严重的不良反应。随着近年来临床医学研究水平的不断提高,有关肿瘤致病与发病机制的相关基本过程也逐渐被阐明,新型的抗肿瘤药物组蛋白去乙酰化酶(HDAC)抑制剂在临床中广泛应用开来。HDAC抑制剂能够作用于患者的肿瘤细胞,使肿瘤细胞的增殖受抑制,诱导肿瘤细胞凋亡,具有非常高的临床应用价值。HDAC抑制剂已经在血液/淋巴系统肿瘤治疗方面取得了一定成果,而HDAC抑制剂在食管癌治疗方面的潜力正在被挖掘。HDAC抑制剂能够抑制食管癌细胞生长并诱导
Abstract:
-

参考文献/References:

[1]Jemal A, Bray F, Center MM,et al.Global cancer statistics[J].CA Cancer J Clin, 2011,61(2):69-90
[2]Lin Y, Totsuka Y, He Y, et al.Epidemiology of esophageal cancer in Japan and China[J].J Epidemiol,2013,23(4):233-242.
[3]Luo Z, Lin C.Enhancer, epigenetics, and human disease[J].Curr Opin Genet Dev,2016,21,36:27-33.
[4]Ahrens TD, Werner M, Lassmann S.Epigenetics in esophageal cancers[J].Cell Tissue Res, 2014,356(3):643-655.
[5]Croagh D, Frede J, Jones PH,et al.Esophageal stem cells and genetics/epigenetics in esophageal cancer[J].Ann N Y Acad Sci, 2014,1325:8-14.
[6]Singh V, Singh LC, Singh AP,et al.Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population[J].Am J Cancer Res, 2015, 15,5(3):979-999.
[7]Icardi L, De Bosscher K, Tavernier J.The HAT/HDAC interplay: multilevel control of STAT signaling[J].Cytokine Growth Factor Rev, 2012,23(6):283-291.
[8]Peserico A, Simone C.Physical and functional HAT/HDAC interplay regulates protein acetylation balance[J].J Biomed Biotechnol, 2011,2011:371832.
[9]Matthews GM, Newbold A, Johnstone RW.Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity[J].Adv Cancer Res, 2012,116:165-197.
[10]Saito T, Nishida K, Furumatsu T, et al.Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes[J].Osteoarthritis Cartilage, 2013,21(1):165-174.
[11]Knipstein J, Gore L.Entinostat for treatment of solid tumors and hematologic malignancies[J].Expert Opin Investig Drugs, 2011,20(10):1455-1467.
[12]Ozaki T, Wu D, Sugimoto H,et al.Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage[J].Cell Death Dis, 2013,4:e610
[13]Lopez G, Bill KL, Bid HK, et al.HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST) [J].PLoS One, 2015, 22,10(7):e0133302.
[14]Makita N, Ninomiya I, Tsukada T, et al.Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells[J].Oncol Rep, 2015,34(3):1185-1192.
[15]李宽钰.线粒体铁代谢与人类疾病的基础研究[J].医学研究生学报,2016,29(1):24-28.
[16]Marks PA. The clinical development of histone deacetylase inhibitors as tar-geted anticancer drugs[J].Expert Opinion on Investigational Drugs, 2010,19:1049-1066.
[17]张国祥,黄淑清,苏标,等. 组蛋白去乙酰化酶抑制剂抗肿瘤机制研究进展[J]. 中国现代药物应用,2014,8(13):238-240
[18]徐伟,刘政,季国忠.血管内皮生长因子在消化系肿瘤中的研究进展[J].医学研究生学报,2009,22(10):1084-1087.
[19]Ozaki T, Wu D, Sugimoto H,et al.Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage[J].Cell Death Dis, 2013,4:e610
[20]刘志欢,傅斌,王共先. 组蛋白去乙酰化酶抑制剂在膀胱肿瘤中的研究进展[J]. 中华临床医师杂志(电子版),2013,7(5):2105-2106.
[21]Murakami K, Matsubara H, Hoshino I,et al.CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells[J].Oncology, 2010,78(1):62-74.
[22]Furutani A, Sowa Y, Fujiwara H, et al.The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells[J].Oncol Res,2014,21(5):281-286.
[23]Tzao C, Jin JS, Chen BH, et al.Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo[J].Dis Esophagus, 2014,27(7):693-702.
[24]Toh Y, Yamamoto M, Endo K,et al.Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma[J].Oncol Rep, 2003,10(2):333-338.
[25]Langer R, Mutze K, Becker K,et al.Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study[J].J Clin Pathol, 2010,63(11):994-998.
[26]Wang F, Qi Y, Li X, et al.HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9[J].Clin Invest Med,2013,36(2):E87-94.
[27]Zhang B, Wang Y, Pang X.Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression[J].Med Oncol, 2012,29(1):340-348.
[28]Chen GQ, Tian H, Yue WM, et al.SIRT1 expression is associated with lymphangiogenesis, lymphovascular invasion and prognosis in pN0 esophageal squamous cell carcinoma[J].Cell Bio Sci, 2014,4:48.
[29]Yang H, Maddipoti S, Quesada A,et al.Analysis of class I and II histone deacetylase gene expression in human leukemia[J].Leuk Lymphoma,2015,56(12):3426-3433.
[30]Makita N, Ninomiya I, Tsukada T, et al.Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells[J].Oncol Rep, 2015,34(3):1185-1192.
[31]Shoji M, Ninomiya I, Makino I,et al.Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma[J].Int J Oncol, 2012,40(6):2140-2146.
[32]Cˇincˇárová L, Zdráhal Z, Fajkus J.New perspectives of valproic acid in clinical practice[J].Expert Opin Investig Drugs, 2013,22(12):1535-1547.
[33]Dong Q, Sharma S, Liu H, et al.HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression[J].Toxicol Lett, 2014,224(1):121-129.
[34]Ma J, Guo X, Zhang S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines[J].Mol Med Rep, 2015,11(6):4525-4531.
[35]尹惠卿,张岚,贺付成,等. 丁酸钠对食管癌细胞增殖的影响[J]. 第四军医大学学报,2007,28(13):1158-1160

相似文献/References:

[1]鲁经纬,章磊,樊根涛综述,等.组蛋白去乙酰化酶在软骨发育和骨关节炎中的作用[J].医学研究与战创伤救治(原医学研究生学报),2016,18(06):636.[doi:10.3969/j.issn.1672-271X.2016.06.021]

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金(2017J01223)
更新日期/Last Update: 2018-07-20